CoreAge Rx presents a straightforward online offer for compounded tirzepatide: an advertised $149 monthly price, no membership fee, and an intake reviewed for prescription eligibility. Those details make a useful starting point, but they are not the complete treatment decision.
CoreAge Rx is this publication’s paid featured partner. This review examines public pages checked on September 23, 2026; we did not receive treatment, inspect a dispensed prescription, audit a pharmacy, or independently test clinical outcomes.
The advertised price is clear. Your exact formulation, assigned pharmacy, clinical suitability, and order terms still need confirmation.
What the current offer says
The linked CoreAge offer advertises tirzepatide at $149 per month, describes all doses at the same price, and states there is no membership fee. Its product page also shows a starting price of $149 and describes online assessment and shipping if a prescription is granted.
We treat those statements as the company’s current public offer, not a guarantee for every future order. Before paying, request a written breakdown for the prescription proposed to you. Confirm the amount supplied, billing interval, any laboratory or consultation charges, and what happens if the clinician does not prescribe.
A headline claiming everything is included still leaves practical questions about replacement shipments, changed treatment plans, and cancellation timing. Our cost fieldnote provides a way to keep those answers together. We have not submitted an intake or verified the final price of an individual order.
Sources: CoreAge Rx: Current promotional offer · CoreAge Rx: Tirzepatide product page
Which medicine would you receive?
CoreAge’s public product material identifies compounded medication. Compounded tirzepatide is not FDA-approved Zepbound or Mounjaro. FDA does not review a compounded drug’s safety, effectiveness, or quality before marketing, and a shared ingredient does not establish equivalent outcomes.
Ask the clinician why an approved product would not meet your medical needs, what is in the proposed formulation, and what evidence supports that choice. The current regulatory context matters because FDA has resolved the tirzepatide shortage and explains restrictions on making essentially copies of commercially available drugs.
Our compounding guide covers those distinctions. This review does not determine whether a particular CoreAge prescription is appropriate or compliant; that requires information about the individual patient and order that public marketing pages do not provide.
Sources: CoreAge Rx: Tirzepatide product page · FDA: Concerns with unapproved GLP-1 drugs · FDA: GLP-1 supply and compounding policy · FDA: Compounding questions and answers
Pharmacy assignment is an order-specific question
CoreAge’s help center says it works with multiple licensed compounding pharmacies and assigns a pharmacy after clinical intake review. It says location, state requirements, and the prescribed treatment influence that assignment. We therefore do not present one pharmacy as the verified dispenser for every CoreAge customer.
Ask for the assigned pharmacy’s legal name, address, phone number, and relevant state licensing information before relying on a shipment promise. Use the state-board resources linked through FDA’s BeSafeRx guidance. Ask the pharmacist to explain storage, the beyond-use date, concentration, and the measuring device supplied with your prescription.
If the pharmacy or formulation changes at refill, repeat that conversation. An earlier label is not a universal set of instructions for another container. This publication has not inspected pharmacy operations or tested the contents of a shipped preparation.
Sources: CoreAge Rx: Dispensing pharmacy FAQ · FDA: Buying medicines from online pharmacies · FDA: Concerns with unapproved GLP-1 drugs
Assess the care arrangement, not just the checkout
The product page describes physician review and ongoing provider access. Ask who will actually prescribe for you, whether that clinician can treat you in your state, and how follow-up is scheduled. Customer-support availability is not the same as a guaranteed clinical response time.
Before starting, request a plan for side effects, missed communications, travel, and interruptions to treatment. Ask what happens if tirzepatide is unsuitable or your medical needs change. A convenient enrollment flow cannot answer those clinical questions by itself.
Read our first-appointment guide and selected safety warnings. They are preparation tools, not substitutes for an assessment or the instructions attached to your own prescription.
Sources: CoreAge Rx: Tirzepatide product page · HHS: Licensing across state lines · Lilly: Zepbound prescribing information · Lilly: Mounjaro prescribing information
How to use this review in a comparison
CoreAge’s simple advertised billing structure may be a practical point to investigate. It is not proof of better medical care or a better result. We give CoreAge prominent placement because of a commercial relationship, and do not award an independent clinical score.
Compare its complete written offer with the Mochi service review and the LillyDirect Zepbound review. The latter concerns access to an approved branded product, so its price should not be treated as a like-for-like comparison with a compounded preparation.
A useful decision requires answers about product identity, clinical suitability, pharmacy, cost, and follow-up. If any of those remain vague, keep them on your visit notebook rather than filling the gap with an assumption about the brand.
Sources: CoreAge Rx: Current promotional offer · Mochi Health: Public care and pricing FAQs · LillyDirect: Zepbound self-pay options · FDA: Managing medicine benefits and risks
The source shelf
- CoreAge Rx: Current promotional offer
Advertised terms only; no checkout, prescription or pharmacy product was tested.
- CoreAge Rx: Tirzepatide product page
Public product description; verify the selected offer and clinical eligibility.
- FDA: Concerns with unapproved GLP-1 drugs
Compounding, fraudulent labels, dosing errors and the limits of adverse-event reports. Checked September 23, 2026.
- FDA: GLP-1 supply and compounding policy
Shortage resolution and restrictions on essentially copies; availability requires current professional assessment.
- FDA: Compounding questions and answers
Compounded medicines do not undergo FDA premarket review like approved drugs.
- CoreAge Rx: Dispensing pharmacy FAQ
Provider description of pharmacy matching; actual dispensing pharmacy must be confirmed for an order.
- FDA: Buying medicines from online pharmacies
Checks for prescription requirements, licensing, contact details and pharmacy support.
- HHS: Licensing across state lines
The patient location affects telehealth licensure requirements; a place page does not verify a provider.
- Lilly: Zepbound prescribing information
Current approved-product label, revised August 2026; does not establish equivalence of compounded preparations.
- Lilly: Mounjaro prescribing information
Product-specific diabetes indications and safety information. Not an interchangeable label for compounded tirzepatide.
- Mochi Health: Public care and pricing FAQs
Membership, medication and insurance pathways must be distinguished.
- LillyDirect: Zepbound self-pay options
Current prices vary by presentation and prescribed strength; higher-strength promotional pricing has refill timing conditions.
- FDA: Managing medicine benefits and risks
General questions for clinical decision-making and medication follow-up.
